<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102682">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02129660</url>
  </required_header>
  <id_info>
    <org_study_id>DRM04-HH02</org_study_id>
    <nct_id>NCT02129660</nct_id>
  </id_info>
  <brief_title>Comparator Study of the Effect of DRM04B and DRM 04 in Subjects With Axillary Hyperhidrosis</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind Vehicle-Controlled Comparator Study of the Effect of DRM04B and DRM04 in Subjects With Axillary Hyperhidrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermira, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety of 2 doses of DRM04B compared to 2 doses of
      DRM04 and vehicle (5 treatment arms) for the treatment of axillary hyperhidrosis when
      applied once daily for 4 weeks followed by a 2-week post-dose period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a  randomized, double-blind, vehicle controlled, parallel group, comparator study
      designed to assess the safety, efficacy and pharmacokinetics of two doses of DRM04B compared
      to two doses of DRM04 compared to vehicle, 5 treatment arms.

      Efficacy will be assessed through gravimetric assessment of sweat production using Patient
      Reported Outcome and the Hyperhidrosis Disease Severity Score (HDSS).

      Safety will be assessed through adverse events, local skin responses, serum chemistry and
      hematology laboratory testing, ECGs, physical examination and vital signs.

      PK blood samples will be taken study subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of subjects who have a minimum 1-grade improvement in HDSS from Baseline at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects who have a minimum 2-grade improvement in HDSS from Baseline at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in the gravimetrically measured sweat production from Baseline to Week 4</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in the gravimetrically measured sweat production from Baseline to Week 6</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects who have a minimum 1-grade improvement in HDSS from Baseline at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided</description>
  </primary_outcome>
  <other_outcome>
    <measure>Patient Reported Outcome absolute change in the questions from Baseline to Week 4</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcome change in the questions from Baseline to Week 6</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcome Shift tables comparing Baseline to Week 4 and Week 6 for each treatment group</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcome change in the question 6 from Baseline to Week 4 and Week 6</measure>
    <time_frame>Week  6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcome exploratory PK/PD relationships will be assessed</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hyperhidrosis</condition>
  <arm_group>
    <arm_group_label>Dose 1 of DRM04B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRM04B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 of DRM04B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRM04B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1 of DRM04</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DRM04</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 of DRM04</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DRM04</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 1 of DRM04B</intervention_name>
    <description>Not provided</description>
    <arm_group_label>Dose 1 of DRM04B</arm_group_label>
    <other_name>Not provided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 2 of DRM04B</intervention_name>
    <description>Not provided</description>
    <arm_group_label>Dose 2 of DRM04B</arm_group_label>
    <other_name>Not provided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 1 of DRM04</intervention_name>
    <description>Not provided</description>
    <arm_group_label>Dose 1 of DRM04</arm_group_label>
    <other_name>Not provided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 2 of DRM04</intervention_name>
    <description>Not provided</description>
    <arm_group_label>Dose 2 of DRM04</arm_group_label>
    <other_name>Not provided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Not provided</description>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>Not provided</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 years of age or older.

          -  Primary, axillary hyperhidrosis of at least 6 months duration.

          -  Hyperhidrosis Disease Severity Score (HDSS) of 3 or 4 at baseline.

          -  For each axilla, a baseline gravimetric measurement of sweat production of at least
             50 mg over 5 minutes, while at rest, at room temperature.

          -  Male or non-pregnant, non-lactating females.

        Exclusion Criteria:

          -  Current pregnancy or lactation.

          -  Prior surgical procedure for hyperhidrosis.

          -  Any prior axillary treatment with an anti-hyperhidrosis medical device

          -  Interventional investigational product in the past 6 months prior to
             Baseline/Day 1.

          -  Prior treatment with botulinum toxin (e.g., Botox®) for axillary hyperhidrosis within
             1 year of Baseline/Day 1.

          -  Subjects with clinically significant abnormalities in laboratory values.

          -  Subjects with a positive Hepatitis or HIV.Hepatitis B surface antibody positive is
             allowed only if the subject has a history of having received Hepatitis B vaccination
             and there are no clinically significant abnormalities in screening liver function
             tests.

          -  Treatment with cholinergic, serotonergic antagonists, and dopamine partial agonists
             thought to relieve antidepressant-induced hyperhidrosis, within one month prior to
             Baseline/Day 1.

          -  Treatment with psychotherapeutic medications for less than 4 months prior to
             Baseline/Day 1.

          -  Treatment with topical or systemic anticholinergics, adrenergic agonists (clonidine),
             or beta-blockers within 4 weeks of the baseline visit

          -  Prior treatment with axillary iontophoresis within 4 weeks of Baseline/Day 1.

          -  Any previous IV or oral treatment with the study drug.

          -  Prior treatment with the topical study drug in a previous trial.

          -  Axillary use of nonprescription or prescription antiperspirants within 2 weeks of
             study enrollment.

          -  Presence of a condition, within 10 years of enrollment, that may cause secondary
             hyperhidrosis

          -  Menopausal women who have had symptoms of menopause such as sweating or flushing
             within 3 years of the study may not be enrolled.

          -  Known history of Sjögren's syndrome or Sicca syndrome.

          -  History of glaucoma, inflammatory bowel disease, toxic megacolon, or febrile illness.

          -  Men with a history of urinary retention requiring catheterization due to prostatic
             hypertrophy or severe obstructive symptoms of prostatic hypertrophy.

          -  Abnormal findings on screening ECG deemed clinically significant by the Investigator.

          -  History or presence of ventricular arrhythmias, atrial fibrillation, atrial flutter.
             History of other supraventricular tachycardia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynne M. Deans, MT</last_name>
    <role>Study Director</role>
    <affiliation>Dermira, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie Reed</last_name>
    <phone>201-587-0500</phone>
    <phone_ext>3362</phone_ext>
    <email>ereed@tklresearch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynne M Deans, MT</last_name>
    <phone>650-421-7484</phone>
    <email>lynne@dermira.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>California Dermatology &amp; Clinical Research Institute</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alisa Messina, RN</last_name>
      <phone>760-203-3839</phone>
      <phone_ext>103</phone_ext>
      <email>amessina@cdcrinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Stacy R Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center For Dermatology Clinical Research</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galyna Cavallaro, CRC</last_name>
      <phone>510-797-0110</phone>
      <email>galynac@centerforderm.com</email>
    </contact>
    <investigator>
      <last_name>Sunil S. Dhawan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew Zook, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shideler Clinical Research Center</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haber Dermatology and Cosmetic Surgery</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Rakes</last_name>
      <phone>216-932-5200</phone>
      <email>krakes@haberderm.com</email>
    </contact>
    <investigator>
      <last_name>Robert Haber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Koliha, RN</last_name>
      <phone>206-267-2100</phone>
      <email>ckoliha@daseattle.com</email>
    </contact>
    <investigator>
      <last_name>Peter J Jenkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Clinical Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Beth Lee, CCRC</last_name>
      <phone>206-522-3330</phone>
      <phone_ext>111</phone_ext>
      <email>mlee@seattlewomens.com</email>
    </contact>
    <investigator>
      <last_name>Robin Kroll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DeAnn Dickinson, BS, RN, CCRS</last_name>
      <phone>813-849-5566</phone>
      <email>Lpea@olympianresearch.com</email>
    </contact>
    <investigator>
      <last_name>William P Werschler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc.</name>
      <address>
        <city>Montreal</city>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Barbin</last_name>
      <phone>514-521-3111</phone>
      <phone_ext>x214</phone_ext>
      <email>vbarbin@innovaderm.ca</email>
    </contact>
    <investigator>
      <last_name>Catherine Maari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>April 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
